This is the authors' abstract. We don't add key points for this paper.
The COVID-19 pandemic, caused by the SARS-CoV-2 virus has become a public health emergency with more than 120 million confirmed cases and 2 million deaths worldwide, as of 18 March 2021. Several studies report that the pandemic has led to a further increase and inappropriate use of antibiotics, which might have a long-term impact on public health due to antibiotic bacterial resistance (AMR). The present study aims to: i) provide updated information on antibiotic prescriptions in patients with COVID-19, ii) discuss issues related to irrational use of antibiotics and, iii) provide guidelines to face the growing threat of antibiotic-resistant bacteria. This is a summary review on issues and scientific aspects related to the current state of knowledge in the field, as a result of the selection of publications until March 2021. The rationale for antibiotic treatment in COVID-19 patients seems to be related to the previous experience on bacterial superinfection in influenza, where the rate of coinfection/secondary bacterial pneumonia was 11-35% in hospitalized patients. On the other hand, the currently limited evidence suggests that in COVID-19 this incidence is much lower. Several studies report a high prevalence (more than 70%) of broadspectrum antibiotic use in patients with COVID-19. In fact, the most prescribed antibiotics were fluoroquinolones, third-generation cephalosporins, piperacillin/tazobactam and carbapenems. Moreover, empirical antibiotic prescriptions seem to be based on clinical symptoms, rather than on laboratory markers of inflammation or radiology findings. High rates of empiric prescriptions of broad-spectrum antibiotics were reported during the COVID-19 pandemic, which suggests that more guidance on the use of antibiotics is needed. Guidelines need to be repurposed and promoted even in these difficult times where there is a massive pressure on all healthcare workers. A close and continuous surveillance of the 118 AJNTS No 54 / 2022 (XXVII) antibiotic use, along with national recommendations and continuous education, might contribute to the improvement of the appropriate use of antibiotics and mitigate the consequences due to AMR. Further investigations through larger and prospective studies are required to help and guide stewardship practices.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bozo et al. (2022) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: